Alnylam's gene-silencing drug meets main goal in late-stage study
March 06, 2019 at 07:08 AM EST
Alnylam Pharmaceuticals Inc said on Wednesday its gene-silencing drug for treating a rare, painful disease met the main goal in a late-stage trial.
